A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single, Ascending, Subcutaneous Doses of FT-104 HCl In Healthy Volunteers
Latest Information Update: 02 Aug 2022
At a glance
- Drugs FT-104 (Primary)
- Indications Mood disorders
- Focus Adverse reactions
- Sponsors Field Trip Health
- 21 Jul 2022 According to a Field trip health media release, the company anticipates reporting results from the study in Q4-2022.
- 21 Jul 2022 According to a Field trip health media release, the company has announced the first successful dosings in the trial.
- 21 Jul 2022 Status changed from planning to recruiting, according to a Field trip health media release.